Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + mFOLFOX6 versus bevacizumab + mFOLFOX6 in first-line KRAS wild-type metastatic colorectal cancer
2008-004281-71Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Panitumumab + mFOLFOX6 with Bevacizumab + mFOLFOX6 (2 arms). Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
panitumumabbevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-004281-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004281-71.